Summit Therapeutics (SMMT) Debt to Equity (2019 - 2024)
Summit Therapeutics filings provide 5 years of Debt to Equity readings, the most recent being $2.26 for Q1 2024.
- Quarterly Debt to Equity rose 201.93% to $2.26 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $2.26 through Mar 2024, up 201.93% year-over-year, with the annual reading at $1.29 for FY2023, 67.04% down from the prior year.
- Debt to Equity hit $2.26 in Q1 2024 for Summit Therapeutics, up from $1.29 in the prior quarter.
- Across five years, Debt to Equity topped out at $3.9 in Q4 2022 and bottomed at -$0.0 in Q1 2020.
- Average Debt to Equity over 4 years is $1.24, with a median of $0.79 recorded in 2023.
- The largest annual shift saw Debt to Equity tumbled 67.04% in 2023 before it surged 201.93% in 2024.
- Summit Therapeutics' Debt to Equity stood at -$0.0 in 2020, then soared by 260558.23% to $3.9 in 2022, then tumbled by 67.04% to $1.29 in 2023, then skyrocketed by 75.73% to $2.26 in 2024.
- Per Business Quant, the three most recent readings for SMMT's Debt to Equity are $2.26 (Q1 2024), $1.29 (Q4 2023), and $0.84 (Q2 2023).